MARKER THERAPEUTICS, INC. Increase (Decrease) in Deferred Revenue
MARKER THERAPEUTICS, INC. (MRKR) reported Increase (Decrease) in Deferred Revenue of $974.80 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-03-18
- MARKER THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was -$378.18K.
- MARKER THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $0.00.
- MARKER THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2022-12-31 was $0.00.
- MARKER THERAPEUTICS, INC. increase (decrease) in deferred revenue for the quarter ending 2022-09-30 was $0.00.
- MARKER THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2025 was $974.80K.
- MARKER THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2022 was -$1.15M, a 200.00% decline from fiscal 2021.
- MARKER THERAPEUTICS, INC. increase (decrease) in deferred revenue for fiscal 2021 was $1.15M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$378.18K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$378.18K derived: sum of 2 quarters · filed 2026-03-18 | $974.80K 10-K · filed 2026-03-18 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.35M 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $1.35M 10-Q · filed 2025-08-14 | |||
| 2023-09-30 | $107.53K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $0.00 derived: sum of 2 quarters · filed 2024-03-26 | -$181.86K derived: sum of 3 quarters · filed 2024-03-26 | -$1.15M 10-K · filed 2024-03-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$181.86K derived: sum of 2 quarters · filed 2023-11-09 | -$1.15M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$181.86K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$1.15M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$964.32K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $1.15M 10-K · filed 2023-03-22 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |